Back to results

Phase 1/2 Study of M3814 (peposertib) in Combination with Hypofractionated Radiotherapy for the Treatment of Locally Advanced Pancreatic Adenocarcinoma

Protocol #

NCI-10366

Trial Phase:

Phase I/II

Principal Investigator:

Fields, Emma

Cancer Type
  • Pancreas
Study Site
  • Virginia Commonwealth University

Patients must have pathologically confirmed pancreatic adenocarcinoma.
Received 4-6 months of induction chemotherapy with either FOLFIRINOX or gemcitabine/abraxane, as per standard of care.
Patients must have locally advanced pancreatic cancer according to NCCN Guidelines (Version 1.2020) on CT scan performed within 21 days of registration. Locally advanced disease is defined as any of the following:
For head or uncinate process tumors:
- Solid tumor contact with superior mesenteric artery >180 degrees
- Solid tumor contact with the celiac axis >180 degrees
- Solid tumor contact with the common or proper hepatic arteries >180 degrees
Or
For pancreatic body or tail tumors:
- Solid tumor contact of >180 degrees with the superior mesenteric artery or celiac axis
- Solid tumor contact with the celiac axis and aortic involvement
Or
Unreconstructible superior mesenteric vein or portal vein due to tumor involvement or occlusion (can be due to tumor or bland thrombus)
Age >=18 years.

Get more detailed information at ClinicalTrials.gov

  • Enrollment Status 1
  • Age Group Adult
  • Protocol Type Treatment
  • Research Study Team Carrie Donovan, RN
    Phone: +1 804-628-3836
    Email Study Contact

Click "I'm Interested" to get started. If you have questions, call our study contact.

I'm Interested
Have a question? We're here to help.

Email us or call us with your request.

Send an Email ยป (804) 628-6430
Share: